1316 related articles for article (PubMed ID: 9377569)
1. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of in vitro interleukin 10 production after in vivo administration of interleukin 18 is activated macrophage-dependent and is probably not involved in the antitumor effects of interleukin 18.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Ikegami H; Kurimoto M
Anticancer Res; 1998; 18(6A):4267-74. PubMed ID: 9891477
[TBL] [Abstract][Full Text] [Related]
3. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
4. Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.
Wei H; Zheng X; Lou D; Zhang L; Zhang R; Sun R; Tian Z
Mol Immunol; 2005 May; 42(9):1023-31. PubMed ID: 15829292
[TBL] [Abstract][Full Text] [Related]
5. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
6. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen.
Brooks CG; Holscher M; Urdal D
J Immunol; 1985 Aug; 135(2):1145-52. PubMed ID: 2409140
[TBL] [Abstract][Full Text] [Related]
7. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
Li T; Harada M; Tamada K; Abe K; Nomoto K
Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
[TBL] [Abstract][Full Text] [Related]
8. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
Suzuki R; Suzuki S; Ebina N; Kumagai K
J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
[TBL] [Abstract][Full Text] [Related]
9. [Activation and regulation of macrophages induced by inoculation of cryodestroyed tumor cells].
Tsujino M
Osaka Daigaku Shigaku Zasshi; 1990 Jun; 35(1):180-205. PubMed ID: 2135404
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
11. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
[TBL] [Abstract][Full Text] [Related]
12. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
14. Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity.
Giovarelli M; Santoni A; Jemma C; Musso T; Giuffrida AM; Cavallo G; Landolfo S; Forni G
J Immunol; 1988 Oct; 141(8):2831-6. PubMed ID: 3139768
[TBL] [Abstract][Full Text] [Related]
15. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18.
Lauwerys BR; Renauld JC; Houssiau FA
Cytokine; 1999 Nov; 11(11):822-30. PubMed ID: 10547269
[TBL] [Abstract][Full Text] [Related]
16. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.
Tsutsui H; Nakanishi K; Matsui K; Higashino K; Okamura H; Miyazawa Y; Kaneda K
J Immunol; 1996 Nov; 157(9):3967-73. PubMed ID: 8892629
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 18 induces a synergistic enhancement of interferon gamma production in mixed murine spleen cell-tumor cell cultures: role of endogenous interleukin 12.
Micallef MJ; Tanimoto T; Kohno K; Ikegami H; Kurimoto M
Cancer Detect Prev; 2000; 24(3):234-43. PubMed ID: 10975285
[TBL] [Abstract][Full Text] [Related]
18. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
Yamamoto N; Zou JP; Li XF; Takenaka H; Noda S; Fujii T; Ono S; Kobayashi Y; Mukaida N; Matsushima K
J Immunol; 1995 Mar; 154(5):2281-90. PubMed ID: 7868900
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of interleukin-1 alpha, interleukin-1 beta and interferon-gamma-inducing factor on the production of interferon-gamma by natural killer.
Hunter CA; Timans J; Pisacane P; Menon S; Cai G; Walker W; Aste-Amezaga M; Chizzonite R; Bazan JF; Kastelein RA
Eur J Immunol; 1997 Nov; 27(11):2787-92. PubMed ID: 9394800
[TBL] [Abstract][Full Text] [Related]
20. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
Seo N; Tokura Y; Takigawa M; Egawa K
J Immunol; 1999 Jul; 163(1):242-9. PubMed ID: 10384122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
